Seaport Therapeutics' IPO Details#
Seaport Therapeutics Inc. (SPTX) has announced the pricing of its initial public offering (IPO) at $18.00 per share. This offering includes 14,160,000 shares of common stock and was set at the top of the company's target range.
Financial Expectations#
The clinical-stage therapeutics company anticipates raising approximately $254.9 million from this IPO, before accounting for underwriting discounts, commissions, and other expenses related to the offering. Additionally, Seaport Therapeutics has provided underwriters with a 30-day option to buy an extra 2,124,000 shares at the same IPO price, minus any applicable fees.
Trading Information#
The shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol "SPTX." The offering is projected to close on May 4, 2026, pending standard closing conditions.
Company Focus#
Seaport Therapeutics specializes in developing neuropsychiatric medicines aimed at treating conditions such as depression and anxiety. The company utilizes its unique Glyph platform to create oral therapies that tackle common issues like high first-pass metabolism (the process where the concentration of a drug is significantly reduced before it reaches systemic circulation), low bioavailability (the proportion of a drug that enters circulation when introduced into the body), and side effects linked to established treatment methods.
Regulatory Approval#
A registration statement for the IPO was filed with the Securities and Exchange Commission (SEC) and was declared effective on April 30, 2026.